Home / SLDB : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does SLDB make money? Does SLDB have pricing power? What's the Earnings Whisper? Will SLDB profit more as the business scales? What is SLDB's management track record? Is SLDB's current price justified?

Solid Biosciences Inc.

$8.7 +$3.25 (+59.63%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$9.07

Day Range

$8.65$9.37

Year Range

$3.79$11.45

Market Cap

856.51M

AVG Volume

1.45M

Trailing/Forward PE

-4.55/-

PEG ratio

5.8

Dividend Yield

Next Earnings Date

2026-11-02

Primary Exchange

NASDAQ

Revenue (USD)

SLDB Revenue (USD) by quarter
Period	Revenue (USD)
26 Q2	0
26 Q1	0
25 Q4	0
25 Q3	0
25 Q2	0
25 Q1	0
24 Q4	0
24 Q3	0
24 Q2	0
24 Q1	0

Net Income (USD)

SLDB Net Income (USD) by quarter
Period	Net Income (USD)
26 Q2	-54.8M
26 Q1	-56.74M
25 Q4	-49.79M
25 Q3	-45.78M
25 Q2	-39.48M
25 Q1	-39.28M
24 Q4	-42.6M
24 Q3	-32.73M
24 Q2	-25.07M
24 Q1	-24.3M

Operating Income (USD)

SLDB Operating Income (USD) by quarter
Period	Operating Income (USD)
26 Q2	-57.38M
26 Q1	-57.31M
25 Q4	-49.4M
25 Q3	-48.06M
25 Q2	-41.69M
25 Q1	-40.05M
24 Q4	-39.9M
24 Q3	-35.18M
24 Q2	-27.79M
24 Q1	-26.86M

EBITDA (USD)

SLDB EBITDA (USD) by quarter
Period	EBITDA (USD)
26 Q2	-54.01M
26 Q1	-56.34M
25 Q4	-49.32M
25 Q3	-45.4M
25 Q2	-39.03M
25 Q1	-38.81M
24 Q4	-42.03M
24 Q3	-32.24M
24 Q2	-23.75M
24 Q1	-23.88M

Cash Flows (USD)

SLDB Cash Flows (USD) by quarter
Period	Cash Flows (USD)
26 Q2	-52.74M
26 Q1	-47.4M
25 Q4	-54.12M
25 Q3	-33.56M
25 Q2	-37.79M
25 Q1	-31.98M
24 Q4	-29.85M
24 Q3	-23.72M
24 Q2	-21.75M
24 Q1	-25.34M

EPS (USD)

SLDB EPS (USD) by quarter
Period	EPS (USD)
26 Q2	-0.38
26 Q1	-0.52
25 Q4	-0.53
25 Q3	-0.48
25 Q2	-0.42
25 Q1	-0.59
24 Q4	-0.8
24 Q3	-0.79
24 Q2	-0.61
24 Q1	-0.64

Expenses (USD)

SLDB Expenses (USD) by quarter
Period	Expenses (USD)
26 Q2	57.53M
26 Q1	57.47M
25 Q4	49.97M
25 Q3	48.14M
25 Q2	42.07M
25 Q1	40.18M
24 Q4	40.1M
24 Q3	35.2M
24 Q2	28.07M
24 Q1	27.01M

Cash & Debt (USD)

SLDB Cash & Debt (USD) by quarter
Period	Cash & Debt (USD)
26 Q2	377.68M
26 Q1	381.32M
25 Q4	187.85M
25 Q3	236.14M
25 Q2	268.11M
25 Q1	306.92M
24 Q4	148.92M
24 Q3	171.12M
24 Q2	190.27M
24 Q1	206.07M

Debt ratios

SLDB Debt ratios by quarter
Period	Debt ratios
26 Q2	1.74
26 Q1	1.9
25 Q4	0.97
25 Q3	1.3
25 Q2	1.61
25 Q1	2.07
24 Q4	1.02
24 Q3	1.46
24 Q2	1.87
24 Q1	2.05

Margins

SLDB Margins by quarter
Period	Margins
22 Q2	100%
22 Q1	100%
21 Q4	100%
21 Q3	100%
21 Q2	100%
21 Q1	100%

Return on Capital

SLDB Return on Capital by quarter
Period	Return on Capital
26 Q2	-14.65%
26 Q1	-15.16%
25 Q4	-27.66%
25 Q3	-21%
25 Q2	-15.29%
25 Q1	-13.34%
24 Q4	-31.04%
24 Q3	-19.59%
24 Q2	-12.97%
24 Q1	-11.53%

Shares Outstanding

SLDB Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	143.69M
26 Q1	109.81M
25 Q4	94.73M
25 Q3	94.42M
25 Q2	94.14M
25 Q1	66.34M
24 Q4	53.58M
24 Q3	41.44M
24 Q2	40.93M
24 Q1	38.16M

Book Value Per Share (USD)

SLDB Book Value Per Share (USD) by quarter
Period	Book Value Per Share (USD)
26 Q2	2.6
26 Q1	3.41
25 Q4	1.9
25 Q3	2.31
25 Q2	2.74
25 Q1	4.44
24 Q4	2.56
24 Q3	4.03
24 Q2	4.72
24 Q1	5.52

Total Assets (USD)

SLDB Total Assets (USD) by quarter
Period	Total Assets (USD)
26 Q2	420.58M
26 Q1	422.89M
25 Q4	232.54M
25 Q3	273.91M
25 Q2	308.29M
25 Q1	343.9M
24 Q4	188.66M
24 Q3	211.83M
24 Q2	230.98M
24 Q1	248.69M

Employee Count

SLDB Employee Count by quarter
Period	Employee Count
2025	121
2024	100
2023	88
2022	87
2021	104
2020	70
2019	121
2018	111
2017	60

Free Cash Flow Yield

SLDB Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-15.02%
Sep 26	-12.75%
Aug 26	-13.38%
Aug 26	-14.05%
Aug 26	-14.21%
Aug 26	-15.58%
Jul 26	-19.53%
Jul 26	-20.1%
Jul 26	-18.05%
Jul 26	-15.11%
Jul 26	-14.52%
Jun 26	-16.94%
Jun 26	-18.9%
Jun 26	-22.05%
Jun 26	-23.49%
May 26	-21.45%
May 26	-23.78%
May 26	-22.75%
May 26	-22.86%
May 26	-23.31%
Apr 26	-20.98%
Apr 26	-19.26%
Apr 26	-20.72%
Apr 26	-22.19%
Mar 26	-23.38%
Mar 26	-23.64%
Mar 26	-19.29%
Mar 26	-20.9%
Feb 26	-22.71%
Feb 26	-24.7%
Feb 26	-22.79%
Feb 26	-21.63%
Jan 26	-21.83%
Jan 26	-21.37%
Jan 26	-25.79%
Jan 26	-26.66%
Jan 26	-25.88%
Dec 25	-24.15%
Dec 25	-23.75%
Dec 25	-24.03%
Dec 25	-24.44%
Nov 25	-25.98%
Nov 25	-30.01%
Nov 25	-33.27%
Nov 25	-34.74%
Oct 25	-24.31%
Oct 25	-23.31%
Oct 25	-22.28%
Oct 25	-21.98%
Oct 25	-22.21%
Sep 25	-21.3%
Sep 25	-25.59%
Sep 25	-24.31%
Sep 25	-23.82%
Aug 25	-23.91%
Aug 25	-22.09%
Aug 25	-21.44%
Aug 25	-25.71%
Aug 25	-23.68%
Jul 25	-23.11%
Jul 25	-25.31%
Jul 25	-30.75%
Jul 25	-32.16%
Jun 25	-34.27%
Jun 25	-33.77%
Jun 25	-35.86%
Jun 25	-35.63%
May 25	-50.39%
May 25	-57.56%
May 25	-58.39%
May 25	-68.07%
May 25	-43.59%
Apr 25	-56.93%
Apr 25	-73.68%
Apr 25	-69.59%
Apr 25	-60.22%
Mar 25	-43.49%
Mar 25	-40.84%
Mar 25	-36.91%
Mar 25	-34.66%
Feb 25	-39.6%
Feb 25	-38.29%
Feb 25	-54.92%
Feb 25	-76.85%
Jan 25	-69.6%
Jan 25	-68.95%
Jan 25	-67.69%
Jan 25	-60.15%
Jan 25	-53.46%
Dec 24	-52.2%
Dec 24	-53.21%
Dec 24	-45.08%
Dec 24	-43.83%
Nov 24	-38.83%
Nov 24	-40.91%
Nov 24	-45.64%
Nov 24	-37.71%
Nov 24	-36.66%
Oct 24	-36.92%
Oct 24	-31.94%

Price to Sales

SLDB Price to Sales by quarter
Period	Price to Sales
Aug 23	12.05
Aug 23	11.89
Jul 23	13.89
Jul 23	15.03
Jul 23	15.57
Jul 23	16.72
Jun 23	16.62
Jun 23	17.41
Jun 23	22.24
Jun 23	20.11
Jun 23	19.95
May 23	19.54
May 23	19.03
May 23	20.05
May 23	5.3
Apr 23	4.84
Apr 23	4.82
Apr 23	5.03
Apr 23	4.74
Mar 23	4.7
Mar 23	3.65
Mar 23	2.75
Mar 23	3.29
Mar 23	3.55
Feb 23	4.02
Feb 23	4.64
Feb 23	4.66
Feb 23	5.12
Jan 23	5.12
Jan 23	4.91
Jan 23	4.52
Jan 23	3.92
Dec 22	3.6
Dec 22	3.78
Dec 22	4.39
Dec 22	4.23
Dec 22	4.53
Nov 22	4.47
Nov 22	4.59
Nov 22	4.43
Nov 22	3.11
Oct 22	3.11
Oct 22	3.41
Oct 22	3.48
Oct 22	3.66
Sep 22	3.57
Sep 22	3.92
Sep 22	4.87
Sep 22	5.11
Sep 22	4.95
Aug 22	5.57
Aug 22	6.41
Aug 22	6.11
Aug 22	7
Jul 22	6.23
Jul 22	6.46
Jul 22	6.24
Jul 22	6.06
Jul 22	5.31
Jun 22	5.37
Jun 22	5.33
Jun 22	6.28
Jun 22	5.26
May 22	5.44
May 22	5.04
May 22	4.66
May 22	4.85
Apr 22	5.16
Apr 22	6.58
Apr 22	8.51
Apr 22	9.07
Apr 22	9.96
Mar 22	10.13
Mar 22	11.5
Mar 22	11.37
Mar 22	8.08
Feb 22	9.18
Feb 22	9.98
Feb 22	11.69
Feb 22	12.23
Jan 22	12.44
Jan 22	13.73
Jan 22	15.02
Jan 22	16.95
Dec 21	18.77
Dec 21	20.49
Dec 21	21.13
Dec 21	18.88
Dec 21	18.13
Nov 21	20.12
Nov 21	21.35
Nov 21	23.06
Nov 21	25.31
Oct 21	32.22
Oct 21	32.22
Oct 21	35.71
Oct 21	36.82
Oct 21	37.45
Sep 21	42.37
Sep 21	44.44

Price to Book

SLDB Price to Book by quarter
Period	Price to Book
Sep 26	3.34
Sep 26	3.94
Aug 26	3.75
Aug 26	3.57
Aug 26	3.53
Aug 26	3.22
Jul 26	2.37
Jul 26	2.3
Jul 26	2.56
Jul 26	3.06
Jul 26	3.18
Jun 26	2.73
Jun 26	2.44
Jun 26	2.1
Jun 26	1.97
May 26	2.15
May 26	1.94
May 26	2.03
May 26	3.83
May 26	3.75
Apr 26	4.17
Apr 26	4.54
Apr 26	4.22
Apr 26	3.94
Mar 26	3.74
Mar 26	3.7
Mar 26	3.17
Mar 26	2.92
Feb 26	2.69
Feb 26	2.47
Feb 26	2.68
Feb 26	2.82
Jan 26	2.8
Jan 26	2.86
Jan 26	2.37
Jan 26	2.29
Jan 26	2.36
Dec 25	2.53
Dec 25	2.57
Dec 25	2.54
Dec 25	2.5
Nov 25	2.35
Nov 25	2.04
Nov 25	1.84
Nov 25	1.76
Oct 25	1.96
Oct 25	2.05
Oct 25	2.14
Oct 25	2.17
Oct 25	2.15
Sep 25	2.24
Sep 25	1.87
Sep 25	1.96
Sep 25	2
Aug 25	2
Aug 25	2.16
Aug 25	2.23
Aug 25	1.42
Aug 25	1.54
Jul 25	1.58
Jul 25	1.44
Jul 25	1.19
Jul 25	1.13
Jun 25	1.06
Jun 25	1.08
Jun 25	1.02
Jun 25	1.02
May 25	0.72
May 25	0.63
May 25	0.62
May 25	1.08
May 25	1.68
Apr 25	1.29
Apr 25	1
Apr 25	1.05
Apr 25	1.22
Mar 25	1.69
Mar 25	1.8
Mar 25	1.99
Mar 25	2.12
Feb 25	1.39
Feb 25	1.43
Feb 25	1
Feb 25	0.71
Jan 25	0.79
Jan 25	0.8
Jan 25	0.81
Jan 25	0.91
Jan 25	1.03
Dec 24	1.05
Dec 24	1.03
Dec 24	1.22
Dec 24	1.25
Nov 24	1.41
Nov 24	1.34
Nov 24	1.2
Nov 24	1.46
Nov 24	1.22
Oct 24	1.21
Oct 24	1.4

No video analysis for this stock yet. Request one from our team.

News: SLDB

seekingalpha.com · 10 Sep 2026

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

globenewswire.com · 2 Sep 2026

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare Conference Bo Cumbo, President and CEO, and Gabriel Books, M.D.

seekingalpha.com · 2 Jul 2026

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform with clinical validation momentum. SLDB's $380.7M cash position funds operations into 2028, supporting high-cost Phase 3 SGT-003 trials and multiple pipeline programs without near-term dilution risk. SGT-003's Phase 1/2 data show strong microdystrophin expression and safety, while additional programs in Friedreich's ataxia and CPVT expand addressable markets.